Latham BioPharm Group Revenue and Competitors
Estimated Revenue & Valuation
- Latham BioPharm Group's estimated annual revenue is currently $13.1M per year.
- Latham BioPharm Group's estimated revenue per employee is $198,000
Employee Data
- Latham BioPharm Group has 66 Employees.
- Latham BioPharm Group grew their employee count by 5% last year.
Latham BioPharm Group's People
Name | Title | Email/Phone |
---|---|---|
1 | Director | Reveal Email/Phone |
2 | Director | Reveal Email/Phone |
3 | Director, PMO Lead | Reveal Email/Phone |
4 | Director | Reveal Email/Phone |
5 | Director Medical Devices and Diagnsotics | Reveal Email/Phone |
6 | Director | Reveal Email/Phone |
7 | Associate Director | Reveal Email/Phone |
8 | Director Global Quality Services | Reveal Email/Phone |
9 | Principal Consultant | Reveal Email/Phone |
10 | Senior Consultant | Reveal Email/Phone |
Latham BioPharm Group Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $58.3M | 241 | 20% | N/A | N/A |
#2 | $924.6M | 3002 | -1% | N/A | N/A |
#3 | $16.9M | 77 | 45% | N/A | N/A |
#4 | $19.4M | 88 | 1% | N/A | N/A |
#5 | $72.6M | 300 | 3% | N/A | N/A |
#6 | $7.6M | 43 | 8% | N/A | N/A |
#7 | $3.7M | 24 | -17% | N/A | N/A |
#8 | $39.2M | 162 | 9% | N/A | N/A |
#9 | $3.7M | 24 | 4% | N/A | N/A |
#10 | $30.4M | 138 | N/A | N/A | N/A |
What Is Latham BioPharm Group?
Latham BioPharm Group (LBG) provides the insight, knowledge, and network to unite teams and technologies in the Life Sciences. We provide the depth of expertise necessary to advance your programs, by providing a range of life science services including business development, program management, CMC, quality, regulatory, and strategic consulting with proven experience in biodefense/pandemic response and strategic product development. Our team has an average of over 20 years' experience and many have served as senior executives at companies ranging from start-ups to Fortune 200 companies. A number of us have also held senior level positions within the US government. For over twenty years, we have helped clients identify, evaluate, fund, manage, and monetize opportunities in a wide variety of business segments, generating over $1.5 billion in government funding and over $100 million in licensing fees and investments. On the front end, we assist clients in evaluating critical business decisions and connecting with the target markets to assess opportunities with our Strategy and Portfolio Analysis, Market Research, and Commercial and Government Asset Analysis offerings. We then assist in finding and securing funding through our Business Development and Non-Dilutive Funding Services. Once funded, we drive successful advancement to a targeted value-inflection point through our Program Management and Product Development Team services. Finally, we help monetize the results through Business Development and Mergers and Acquisition support. While all of these services are available a-la-carte, success in each often leads to engagement throughout the life cycle. The power of this experience should not be underestimated. If you are considering a government contract, or are in need of product development expertise to help progress your program to the next investor milestone, contact us today to explore how LBG can put the power of our experience to work for you.
keywords:N/AN/A
Total Funding
66
Number of Employees
$13.1M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Latham BioPharm Group News
Protoqsar Sl, Intertek Group Plc, Bibra Toxicology Advice And Consulting Ltd, Covance Inc. (Labcorp), Latham Biopharm Group, Nsf International,...
Frank Orlowski, Director of Business Development, Latham Biopharm Group Steven Lee, CEO, Eden Biologics Joe Scott, Vice President,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $20.5M | 66 | -39% | $234.9M |
#2 | $8M | 66 | 8% | $20.6M |
#3 | $19.2M | 66 | 0% | N/A |
#4 | $3.5M | 66 | 10% | N/A |
#5 | $15M | 66 | 38% | N/A |